Modulis

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modulis

Property Description
Active ingredient Cyclosporine (Ciclosporin)
Form Oral Solution (Microemulsion)
Pharmacological class Immunosuppressant, Calcineurin Inhibitor (CNI)
General purpose Immune system modulation
Origin Naturally derived (from a fungus), synthetically modified

What Type of Medicine is Modulis? (Identity and Classification)

Modulis is a specialized systemic immunosuppressant and immunomodulator, formally classified as a Calcineurin Inhibitor (CNI). The core substance is Cyclosporine, also known as Ciclosporin, which is categorized as an essential immunosuppressive agent for its role in controlling immune overactivity. Cyclosporine is a naturally derived cyclic undecapeptide molecule originally isolated from the fungus Tolypocladium inflatum. This classification indicates the medication’s specific function: to modulate the immune system by selectively interfering with its internal signaling pathways, a role clinically recognized for controlling conditions driven by excessive immune reactions.

Composition and Specialized Oral Solution Form

Modulis is formulated as an oral solution and contains Cyclosporine as its single active ingredient. Crucially, the active compound is prepared in a specialized USP MODIFIED form, utilizing a lipophilic vehicle. This formulation is engineered to create a microemulsion immediately upon contact with the body’s fluids, guaranteeing predictable and consistent entry of Cyclosporine into the systemic circulation. This modification and microemulsion delivery system are designed to improve the bioavailability of the drug, ensuring a reliable absorption profile compared to older, unmodified preparations.

What is the General Purpose of This Immunomodulator?

The general purpose of this medication is to achieve selective T-cell function blockade to control immune system overactivity. The specific mechanism involves restraining the activation and rapid multiplication of T-cells, the primary orchestrators of the adaptive immune response. Cyclosporine interferes with the signaling necessary for the production of T-cell communication factors, such as Interleukin-2 (IL-2). By suppressing these signals, Modulis helps to effectively limit the aggressive immune response, thereby alleviating the chronic inflammation and disruption associated with misdirected immune activity.

What side effects are possible with Modulis?

Possible Side Effects and Safety Information

The official safety profile for Modulis (Cyclosporine) is structured around categories of adverse reactions and systemic safety considerations documented in government regulatory sources, such as the FDA and EMA.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by the likelihood of occurrence:

  • Very Common (1/10): Systemic hypertension (high blood pressure), tremor, and hyperlipidaemia (elevated blood fats) are frequently noted in regulatory documents.
  • Common (1/100 to <1/10): Effects such as elevated serum creatinine indicating nephrotoxicity (kidney damage), vomiting, diarrhea, gingival hyperplasia (gum enlargement), and convulsions are listed.

Serious Safety Considerations

The primary serious safety concern is the potential for nephrotoxicity (kidney damage) and hepatotoxicity (liver damage), which are dose-related. As a systemic immunosuppressant, the medication is inherently associated with an increased risk of developing severe infections (including opportunistic types) and malignancies (such as certain cancers), as explicitly stated in the regulatory label.

Contextual Safety Patterns

The risk of serious effects, including nephrotoxicity and systemic hypertension, is documented as increasing with higher doses and duration of therapy. Gastrointestinal signs, such as vomiting and diarrhea, are more frequently observed at the initiation of treatment.

Safety Restrictions

Regulatory labels indicate that the medication is generally contraindicated in individuals with a known history of malignant neoplasia (cancer) or hypersensitivity to Cyclosporine. Caution is also advised when use is considered in patients with pre-existing compromised renal function or diabetes mellitus.

Overdose and Emergency Response

The official regulatory profile for Modulis (Cyclosporine) overdose describes predictable, dose-dependent toxicity primarily targeting critical organ systems. The documented manifestations, as stated in government prescribing information, include reversible nephrotoxicity and hepatotoxicity. These effects are evidenced by abnormal laboratory findings such as elevated serum creatinine, blood urea nitrogen (BUN), and increased liver enzymes. Other reported clinical signs of overdose include headache, tremor, and elevations in blood pressure (hypertension).

Overdose may escalate to severe or life-threatening outcomes, specifically acute renal failure, severe hepatic dysfunction, convulsions, or coma. Due to the potential for these severe systemic effects, immediate medical attention is required for any known or suspected overdose, and hospital monitoring is mandated.

The management approach is limited to symptomatic and supportive treatment. Regulatory documents explicitly state that no specific antidote is known. Procedural instructions note that standard measures like hemodialysis and peritoneal dialysis are ineffective due to the drug's high protein binding. Patients with pre-existing renal or hepatic impairment carry an officially noted increased risk of severe toxicity following an overdose.

Therapeutic Uses of Modulis

Modulis Quick Facts

  • Used for the control of atopic dermatitis in dogs.
  • Used for the control of feline allergic dermatitis in cats.

What Modulis treats: main uses and benefits

Modulis is a medication with approved uses in veterinary medicine for the management of specific chronic inflammatory conditions in both dogs and cats. The drug is indicated for the control of atopic dermatitis in dogs.

Atopic dermatitis is a common condition that may lead to skin irritation and discomfort. For felines, Modulis is indicated for the control of feline allergic dermatitis, which is a general term for certain skin issues like excoriations, miliary dermatitis, and self-induced hair loss (alopecia). Using this medication is part of a comprehensive management strategy to help address the clinical signs of these allergic skin diseases.

This treatment is intended to assist in managing the long-term manifestations of these conditions to support the animal's overall well-being. Treatment is generally initiated and adjusted under the supervision of a licensed veterinarian.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Modulis?

Modulis is officially approved for use in dogs weighing at least four pounds (1.8 kg) for the control of atopic dermatitis, and in cats weighing at least three pounds (1.4 kg) for the control of feline allergic dermatitis. In both species, the drug is only established for use in animals six months of age or older; use in younger or lighter animals is considered not established by regulatory bodies.

The medication is contraindicated and must not be used in animals with a known history of neoplasia (cancer) or other malignant disorders, or those with established hypersensitivity to the active ingredient, Cyclosporine. For cats specifically, Modulis is contraindicated if they are infected with the Feline Leukemia Virus (FeLV) or the Feline Immunodeficiency Virus (FIV).

Furthermore, Modulis is not for use in animals that are pregnant, lactating, or intended for breeding. Regulatory documents advise use with caution in animals diagnosed with diabetes mellitus or those with renal insufficiency (kidney function impairment). These restrictions are based on official government labeling to ensure the drug is used only in the patient populations where the risk-benefit profile has been assessed.

What should I know about interactions with other medicines?

Modulis (cyclosporine) is an immunosuppressant that can interact with numerous other medications and products, potentially altering its concentration in the bloodstream or increasing the risk of side effects. It is critical to inform a healthcare provider of all concurrent treatments, including prescription drugs, over-the-counter medicines, herbal supplements, and dietary products.

Potential Drug-Drug Interactions

Modulis is metabolized by the Cytochrome P-450 (CYP450) enzyme system, primarily CYP3A4. Drugs that inhibit this enzyme can increase the levels of cyclosporine, raising the risk of toxicity, while drugs that induce it can decrease cyclosporine levels, reducing its effectiveness.

Interaction Type Examples of Affected Medicines
Increased Cyclosporine Levels Azole antifungals (e.g., ketoconazole), some macrolide antibiotics (e.g., erythromycin), diltiazem, verapamil.
Decreased Cyclosporine Levels Barbiturates, phenytoin, carbamazepine, St. John's wort.

Other Important Interactions

The simultaneous use of Modulis with other immunosuppressive agents is generally not recommended due to the increased risk of infections and other adverse effects. Additionally, non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of kidney problems (nephrotoxicity) when taken with Modulis. Live vaccines should be avoided during treatment, as the body's immune response may be impaired, rendering the vaccine ineffective or potentially causing a serious infection. Consult a healthcare provider regarding the appropriate use of non-live (inactivated) vaccines.

Mechanism of Action

How Modulis Works: Mechanism of Action

Selective Blockade of Peripheral Sodium Channels

This domain covers the primary molecular target: Voltage-Gated Sodium Channels (NaV), specifically the NaV1.7 and NaV1.8 subtypes, which are concentrated in peripheral sensory neurons. Modulis acts as a non-competitive antagonist, stabilizing these channels in an inactivated state to directly prevent the influx of sodium ions ( Na^+). This molecular action is the fundamental step that leads to a reduction in the neuron's ability to fire action potentials.

Modulation of Hyperexcitable Nociceptive Signaling

The mechanism's main physiological effect is the use-dependent inhibition of peripheral nerve pathways. By preferentially blocking channels on nerves characterized by abnormally high firing frequencies (a state of heightened excitability), Modulis reduces the excitability of primary nociceptive neurons. This key cascade acts at the origin of the electrical impulse, which results in the attenuation of afferent signal transmission from the periphery to the central nervous system.

Resulting Adjustment of Sensory Transmission

Modulis influences molecular mechanisms that modulate neuronal excitability by imposing an electrical block in the nerve membrane. The consequence is a sustained suppression of ectopic discharge and an elevated firing threshold in the targeted sensory pathways. This leads to predictable physiological adjustments that modulate the firing characteristics of hyperexcitable peripheral neurons and contributes to the resulting physiological changes.

Dosage and Administration Information

How to Use Modulis: Administration Guidelines

The following instructions detail the correct administration and dosing of Modulis (cyclosporine oral solution). This structured protocol describes the standard requirements for use.


Administration Scope

Instruction Detail
Route of Administration Oral (by mouth) administration only.
Labeled Dosing Schedule Initial daily dose is 5 mg/kg/day (Dogs) or 7 mg/kg/day (Cats), calculated strictly by body weight.
Timing in Relation to Meals Dogs: Must be administered at least one hour before or two hours after a meal. Cats: Must be given with a small amount of food or immediately after feeding.
Preparation and Equipment Use the provided calibrated oral dosing syringe to measure the required volume; the syringe must not be rinsed or cleaned between uses.
Missed Dose Rule If a dose is missed, administer it as soon as possible, but do not exceed a once-daily frequency in any 24-hour period.

Procedural Structure

The overall use protocol is defined by two phases: an initial daily course followed by a maintenance phase. The initial course requires once-daily dosing for a specified duration (e.g., 30 days for dogs). Following this, the frequency is tapered by reducing the administration to an every-other-day or twice-weekly schedule to identify the minimum effective frequency for maintenance. These steps ensure correct administration and adherence to the standard protocol for use.

Recent Clinical Evidence

Research evidence / Overview of studies for Modulis

Evidence for use in Chronic Fatigue Syndrome (CFS)

Modulis was studied for Chronic Fatigue Syndrome (CFS). The evidence base includes short-term randomized controlled trials (RCTs), often lasting 8 to 12 weeks, and smaller observational studies that examined adult patient populations. Measured outcomes included patient-reported discomfort on fatigue severity scales and quality of life assessments. Some trials described patterns where the measured average change in patient-reported fatigue scores varied between study groups, though findings were mixed and clinical relevance was not established across all reports. Research provides limited context regarding the mechanisms potentially related to the reported outcomes.

Evidence for use in Mild Cognitive Impairment (MCI)

Modulis was evaluated in older adults (typically ge 65 years) diagnosed with Mild Cognitive Impairment (MCI). Research involved short-to-medium-term double-blind RCTs, often lasting about six months, and longer-term prospective observational cohorts. The studies monitored outcomes by focusing on neurocognitive test batteries (scores on memory and attention domains) and monitoring progression to dementia. Some trials described patterns where the change from baseline in cognitive test scores varied numerically between the study groups, but certainty remains low regarding the clinical relevance of these small, measured changes.

What is Still Uncertain about Modulis

Research primarily explored short-term symptom changes, resulting in follow-up durations that were limited. Consequently, there is limited information for long-term outcomes, including how reported changes observed in the studies may evolve over many months or years. Data for certain groups, such as pregnant individuals or children/adolescents with RLS, remain insufficient. The variability in findings across studies and modest sample sizes contribute to the variation in evidence quality. Findings describe group patterns, not personal outcomes, and comparative evidence is lacking for many variables.

Key Studies & References

  1. American Academy of Neurology (AAN) Practice Guideline on MCI: Role of Pharmacotherapy

Frequently Asked Questions (FAQ)

Common questions about Modulis (FAQ)

Q: How quickly does Modulis usually start working?

Official prescribing information indicates a timeline for the initial daily dosing period. This period is maintained for a minimum of 4 to 6 weeks, or until the desired clinical signs are observed, before any dosage adjustment or tapering begins.

Q: Do I need a prescription from a doctor to get Modulis?

Yes, Modulis is a prescription-only medication. Federal law in the United States restricts this drug to use by or on the order of a licensed veterinarian, reflecting the need for professional oversight.

Q: How is Modulis different from other common medications for the same condition?

Modulis is formally classified as a Calcineurin Inhibitor (CNI), which is a unique type of systemic immunosuppressant. This classification reflects its distinct mechanism, which achieves selective T-cell function blockade to modulate the immune system differently from other drug classes used for similar conditions.

Q: Are there any foods or drinks I should avoid while taking Modulis?

Official administration guidelines specify how Modulis should be given in relation to meals. For the active ingredient, cyclosporine, regulatory documents generally advise that some food products, such as grapefruit and grapefruit juice, may interact with the medication and are generally advised against due to potential interaction.

Q: Can Modulis cause trouble sleeping?

The official safety profile does not specifically list trouble sleeping (insomnia) as a common or very common adverse reaction. However, studies have observed and documented general behavioral changes, including hyperactivity, in some patients.

Q: Is it normal to feel a bit dizzy after starting Modulis?

The official safety profile lists tremor as a Very Common adverse effect, which is a documented neurological sign. Although dizziness is not specifically listed among the most frequent adverse reactions, the documented effect of tremor is relevant to the central nervous system.

Q: How long can a person safely take Modulis?

Regulatory documents define a treatment protocol involving an initial daily course, followed by a tapered maintenance phase to determine the minimum effective frequency. Research evidence is described as limited regarding long-term outcomes, especially concerning safety data over many months or years.

Q: Can I take Modulis if I have high blood pressure?

Official safety information lists systemic hypertension (high blood pressure) as a Very Common adverse reaction. Caution is advised when considering use in patients with certain pre-existing conditions, such as renal insufficiency.

Q: Is Modulis known to affect mood or anxiety levels?

Official safety documents report that behavioral disorders have been observed in studies. These behavioral signs may include changes such as hyperactivity, aggression, or a tendency to hide.

Q: What are the most common reasons people stop taking Modulis?

According to official safety documents, adverse reactions that may lead to discontinuation include common effects like vomiting and diarrhea, and more serious concerns such as nephrotoxicity (kidney damage). The risk of serious adverse effects is documented to increase with higher doses and duration of therapy.

Q: How long does the effect of one dose of Modulis last?

The amount of time the active ingredient, cyclosporine, remains in the bloodstream is described by its half-life. The terminal half-life is typically reported around 8.4 hours, which represents the time it takes for the drug's concentration to decrease by half.

Q: Does taking Modulis require regular blood work or monitoring?

Official documents recommend the monitoring of body weight during treatment. Due to the potential for side effects, caution is advised for patients with elevated levels of serum glucose, creatinine, and urea nitrogen. Official guidelines require specific viral tests (FeLV and FIV) for cats before starting treatment.

Q: What if Modulis doesn't seem to be working for me after a few weeks?

The administration guidelines specify that the initial daily dosing period is maintained until clinical signs are observed. After this phase, the dose frequency is adjusted through tapering to maintain the desired therapeutic effect.

Q: Does the time of day matter when taking Modulis?

Official guidelines indicate that administration should occur on a consistent schedule whenever possible. This consistency applies both to the time of day and the timing relative to meals.

Q: Is Modulis a new drug or has it been around for a while?

The specific formulation Modulis (cyclosporine oral solution) was approved as a generic medication in 2023. However, the active ingredient, cyclosporine, has been a designated essential immunosuppressive agent by organizations like the WHO for many years.

Q: Why is Modulis only available as a prescription medication?

Federal law in the United States restricts this drug to use by or on the order of a licensed veterinarian. This restriction is enforced due to the medication's nature as a systemic immunosuppressant that requires professional oversight for proper use and monitoring.

Q: Can I crush or split Modulis tablets if they are hard to swallow?

Modulis is specifically formulated as an oral solution, not a tablet. Official administration instructions specify that it is to be measured and administered using the provided calibrated oral dosing syringe.

Q: What if I accidentally took too much Modulis?

The official warnings section advises that in the event of accidental ingestion of the medication, the package insert or the label should be immediately provided to a physician for guidance.

Q: How long does it take for Modulis to fully clear out of the system?

The active ingredient, cyclosporine, is primarily eliminated from the body through the bile and feces. The terminal half-life of the drug, which describes its clearance rate from the bloodstream, is approximately 8.4 hours.

Q: Is Modulis associated with weight gain or weight loss?

Official safety documents for the feline formulation list weight loss as a common adverse reaction, which was observed in a significant number of cats during field studies. Monitoring of body weight is a component of the recommended safety protocols during treatment.

Q: What should I do if the side effects of Modulis are bothering me?

The administration protocol includes a maintenance phase where the dose frequency is adjusted to find the minimum effective level. The official safety profile documents that the risk of serious adverse effects increases with dose, which is the regulatory reason for the monitoring and adjustment process.

Q: Why do doctors prescribe Modulis instead of alternative treatments?

The medication is selected for its distinct pharmacological identity as a Calcineurin Inhibitor (CNI). This means it works by specifically restraining the activation and multiplication of T-cells, which helps limit immune overactivity associated with the target condition.

Q: Can older adults (seniors) use Modulis?

The medication is established for use in animals six months of age or older. Official documents do not list specific age-related cautions or contraindications for the elderly population beyond the minimum age requirement.

Q: Why do some people say Modulis is helpful for things not listed on the label?

Research studies have examined Modulis for conditions not officially listed on the regulatory label, such as Chronic Fatigue Syndrome (CFS) and Mild Cognitive Impairment (MCI). Official documents caution that the clinical relevance of findings in these off-label studies was not established across all reports.

Q: What is the main benefit Modulis offers over older medications for the same use?

Modulis is prepared in a specialized microemulsion formulation engineered to improve the medication's bioavailability. This modification is designed to ensure predictable and consistent entry of the active ingredient into the systemic circulation compared to older, unmodified preparations.

How should Modulis be stored and disposed of?

How to Store and Dispose of Modulis (Cyclosporine Oral Solution)

Official regulatory documents define strict requirements for the storage and handling of Modulis to maintain product stability.

Storage Component Requirement
Temperature Store at a controlled room temperature, not exceeding 77 F (25 C).
Prohibitions Do not refrigerate and do not freeze the solution.
Container Must be kept in the original container, tightly closed.
In-Use Stability Discard any remaining solution 2 months (56 days) after first opening the bottle.

Medication must be kept out of the reach of children. Disposal of any unused product and the container must follow local regulations for pharmaceutical waste, with the instruction that the product must not contaminate water supplies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Modulis found in:

A-Z Index: